Management

Chief Executive Officer (CEO)

Dr Namyong Kim

Namyong Kim brings with him more than 15 years of experiences in scientific research and technical management in the development of biotech instrumentation. He holds more than 10 patents and patent applications, and has published a number of scientific publications in peer-reviewed journals.

Prior to coming to Singapore, Namyong was based in the US where he had the opportunity to work with early-stage high-tech ventures and multinational companies. At BioTrove, he led a chemistry group in the development of the OpenArray platform, a miniaturized chip-based platform for homogeneous biological assays. Earlier to that, he worked with the two-cofounders of Arradial as the Director of Chemistry, and contributed to growing the company into a 15-person team. At Agilent Technologies, he worked on the optimization and commercialization of DNA microarrays as a Research Scientist.

Namyong received his PhD in Chemistry from the Massachusetts Institute of Technology (MIT), and his BSc from the Korea Advanced Institute of Science and Technology (KAIST).

Board of Directors

Chairman and Managing Director, Zicom Group Limited

Mr Giok Lak Sim

Mr Sim is qualified as an accountant in 1967. He is Fellow of the Australian Society of Certified Practising Accountants and Fellow of the Institute of Certified Public Accountants, Singapore.

Mr Sim is a founder of Zicom Holdings Pte Ltd in 1978 and was appointed to the board on 5 April 1995. He has been Chairman and Managing Director of Zicom Group Limited and Executive Chairman of all subsidiaries. He is a true entrepreneur and savvy business executive with expertise in public accounting, corporate development, financial and industrial management and international trade.

Mr Sim also holds the position of a Chairman of BioBot Surgical Pte Ltd, a surgical robotic company and a director of HistoIndex Pte Ltd, a company involved in the development of histology indexing. He is the recipient of the Ernest & Young Entrepreneur of the Year (Industrial Products) 2008 award in Singapore.

CEO, Biobot Surgical Pte Ltd

Chew Loong Yap

Mr Yap is the CEO of Biobot Surgical Pte Ltd, consultant to Med Tech companies, and active Angel Investors in Med Tech start-up companies, in Singapore and China. He was the Executive Vice President and General Manager of Exploit Technologies Pte Ltd, the marketing and commercialization arm of Agency of Science, Technology and Research (A*STAR), and then the General Manager of Puth Medical China. He has more than 30 years of managerial and business experiences in manufacturing, operations, sales and marketing in medical technology products. Prior to Exploit Technologies Pte Ltd, he worked for Becton Dickenson (BD), a multi-billion dollar multinational Fortune 500 company with headquarter in the USA. He spent over 18 years at BD in various positions as Manufacturing Manager, Plant Manager and then Country General Manager of BD China/Hong Kong. He worked also for ST Kinetics in Singapore in various managerial roles in manufacturing. He received his Bachelor Degree in Engineering from University of Malaya, and MSc Degree in Industrial and System Engineering and MBA from National University of Singapore.

CEO, Experimental Therapeutic Centre (ETC)

Dr Alex Matter

Dr Matter is best known for his contribution to the development of Glivec/ Gleevec, one of the world’s first tyrosine kinase inhibitor drugs for cancer therapy. He led a team of around 200 scientists at Novartis to discover and optimize the lead compound, bringing it all the way through its first clinical trial in 1998. In a short span of 3 years, Gleevec was given a rare, fast track FDA approval in 2001.

Prior to ETC, Dr Matter was the founding director for the Novartis Institute for Tropical Diseases (NITD) in 2003. Under his leadership, NITD successfully implemented research programs in the areas of dengue fever, tuberculosis and malaria attracting major grants from the Bill&Melinda Gates Foundation and the Wellcome Trust.

A medical doctor by training, Dr. Matter received his medical degree from the University of Basel and did immunology and pathology research in Switzerland, Britain, France and the US before entering into the pharmaceutical industry. He has published more than 100 scientific articles plus several book chapters in the area of oncology and hematology. He is the recipient of the 13th Warren-Alpert prize and the AACR-Bruce F. Cain Memorial Award.

Executive Director, Zicom Group Limited

Mr Kok Hwee Sim

Mr Sim is Executive director of ZGL and director of various group’s subsidiaries. He has a range of experiences in and is responsible for group corporate development, restructuring, business valuations and acquisitions.

Mr Sim received his Master of Financial Engineering degree from Columbia University and Bachelor of Industrial and Operations Engineering (Magna Cum Laude) degree from the University of Michigan.

Chief Executive Officer (CEO), Curiox Biosystems

Dr Namyong Kim

Namyong Kim brings with him more than 15 years of experiences in scientific research and technical management in the development of biotech instrumentation. He holds more than 10 patents and patent applications, and has published a number of scientific publications in peer-reviewed journals.

Prior to coming to Singapore, Namyong was based in the US where he had the opportunity to work with early-stage high-tech ventures and multinational companies. At BioTrove, he led a chemistry group in the development of the OpenArray platform, a miniaturized chip-based platform for homogeneous biological assays. Earlier to that, he worked with the two-cofounders of Arradial as the Director of Chemistry, and contributed to growing the company into a 15-person team. At Agilent Technologies, he worked on the optimization and commercialization of DNA microarrays as a Research Scientist.

Namyong received his PhD in Chemistry from the Massachusetts Institute of Technology (MIT), and his BSc from the Korea Advanced Institute of Science and Technology (KAIST).